Dual use is not an intermediate condition on the way from cigarettes to “switching completely” or quitting

Discussion of potential harm reduction associated with the use of e-cigarettes assumes that smokers will “switch completely” from cigarettes to e-cigarettes or stop both tobacco products. Advocates of this view, including the US FDA, recognize and accept that this process may include a period of dual use in which smokers use both products. Now JosefContinue reading “Dual use is not an intermediate condition on the way from cigarettes to “switching completely” or quitting”

Dual cigarette and e-cig use increases human risk of lung cancer 40 times

As summarized in an earlier blog post, exposure to e-cigarette aerosol accelerates tumore growth and spread (metastasis) among established cancers. This effect is distinct from actually causing the cancer (i.e., carcinogenesis). Indeed, propylene glycol and vegetable glycerine (PG/VG), the primary solvents in e-liquid and which have been assumed to be inert are major causes ofContinue reading “Dual cigarette and e-cig use increases human risk of lung cancer 40 times”

E-cig advocates publish results showing e-cig users have more respiratory symptoms than nonsmokers

E-cigarette advocate Riccardo Polosa, along with pro-harm reduction colleagues from around the world, recently published Respiratory symptoms among e-cigarette users without an established smoking history in the VERITAS cohort. Their paper presents strong evidence that sole e-cigarette users (i.e., people who are not also smoking cigarettes) are significantly more likely to experience respiratory symptoms thanContinue reading “E-cig advocates publish results showing e-cig users have more respiratory symptoms than nonsmokers”

Criticism of our meta-analysis of e-cigarettes and disease and our response is published

NEJM Evidence has published two letters to the editor that raised questions about our meta-analysis, Population-Based Disease Odds for E-Cigarettes and Dual Use versus Cigarettes that concluded that for cardiovascular disease, stroke and metabolic disorder e-cigarette risks are similar to cigarettes and for respiratory and oral disease, while lower risk than cigarettes, the risks areContinue reading “Criticism of our meta-analysis of e-cigarettes and disease and our response is published”

New meta-analysis of e-cigs and cardiovascular disease shows increased risks

Chen Chen and colleagues recently published Assessing the association between e-cigarette use and cardiovascular disease: A meta-analysis of exclusive and dual use with combustible cigarettes that found significantly elevated cardiovascular disease risk in dual users (people who use both e-cigarettes and cigarettes) and former smokers who had switched to e-cigarettes compared to people who hadContinue reading “New meta-analysis of e-cigs and cardiovascular disease shows increased risks”

Implications of new RCT showing similar effects on quitting for nicotine e-cigs vs varenicline

Almost all the randomized controlled trials of e-cigarettes as clinical interventions for smoking cessation have compared e-cigarettes to nicotine replacement therapy.  Varenicline, which is a prescription medication that works by blocking nicotine receptors rather than replacing the nicotine that cigarettes provide, is more effective than NRT.  Anna Tsiku and colleagues new paper “Electronic Cigarettes vsContinue reading “Implications of new RCT showing similar effects on quitting for nicotine e-cigs vs varenicline”

English vaping reverses nicotine decline

In England, the country that has most aggressively embraced e-cigarettes, authorities have long minimized the effects of e-cigarettes on youth and argued that they were improving public health by attracting smokers or displacing cigarette use. Now Harry Tattan-Birch and colleagues have blown those arguments away. Their May 23, 2024 paper Trends in vaping and smokingContinue reading “English vaping reverses nicotine decline”

FDA did the right thing when it withdrew its 2022 Juul marketing denial order; it should finish the job quickly by prohibiting Juul on solid grounds

On June 6, 2024, two years after the FDA issued, then suspended its Marketing Denial Order for Juul e-cigarettes based on narrow toxicology issues, FDA formally withdrew the MDO. This does not mean that the FDA has authorized Juul for sale in the US, it just lets FDA start over in its assessment of whetherContinue reading “FDA did the right thing when it withdrew its 2022 Juul marketing denial order; it should finish the job quickly by prohibiting Juul on solid grounds”

Why is the Royal College of Physicians concluding the ecigs help smokers quit when a large body of evidence shows that, as consumer products, they don’t?

On April 18, 2024 the UK Royal College of Physicians published E-cigarettes and Harm Reduction: An Evidence Review, the latest in a series of reports it has published since 2007 endorsing e-cigarettes for harm reduction.  In this report, the RCP recommends that “e-cigarettes should be promoted as an effective means of helping people who smokeContinue reading “Why is the Royal College of Physicians concluding the ecigs help smokers quit when a large body of evidence shows that, as consumer products, they don’t?”

Why is the Royal College of Physicians concluding e-cigs reduce harm while ignoring the substantial associations between e-cigs and actual disease?

On April 18, 2024 the UK Royal College of Physicians published E-cigarettes and Harm Reduction: An Evidence Review, the latest in a series of reports it has published since 2007 endorsing e-cigarettes for harm reduction.  The report covers a wide range of topics, including assessing the health risks of e-cigarettes, the central question on whetherContinue reading “Why is the Royal College of Physicians concluding e-cigs reduce harm while ignoring the substantial associations between e-cigs and actual disease?”